[go: up one dir, main page]

SI0975347T1 - Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize - Google Patents

Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize

Info

Publication number
SI0975347T1
SI0975347T1 SI9830909T SI9830909T SI0975347T1 SI 0975347 T1 SI0975347 T1 SI 0975347T1 SI 9830909 T SI9830909 T SI 9830909T SI 9830909 T SI9830909 T SI 9830909T SI 0975347 T1 SI0975347 T1 SI 0975347T1
Authority
SI
Slovenia
Prior art keywords
agonists
adenylate cyclase
cyclyse
guanyl
synergistic combination
Prior art date
Application number
SI9830909T
Other languages
English (en)
Inventor
Rolf Beume
Dieter Flockerzi
Klaus-Dieter Beller
Friedrich Grimminger
Norbert Suttorp
Christian Schudt
Original Assignee
Nycomed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Gmbh filed Critical Nycomed Gmbh
Publication of SI0975347T1 publication Critical patent/SI0975347T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI9830909T 1997-02-28 1998-02-24 Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize SI0975347T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19708049 1997-02-28
PCT/EP1998/001047 WO1998037894A1 (de) 1997-02-28 1998-02-24 Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten
EP98913584A EP0975347B1 (de) 1997-02-28 1998-02-24 Synergistische kombination von pde-hemmern und adenylatcyclase-agonisten bzw. guanylcyclyse-agonisten

Publications (1)

Publication Number Publication Date
SI0975347T1 true SI0975347T1 (sl) 2008-08-31

Family

ID=7821764

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9830909T SI0975347T1 (sl) 1997-02-28 1998-02-24 Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize

Country Status (12)

Country Link
US (1) US6333354B1 (sl)
EP (1) EP0975347B1 (sl)
JP (2) JP2001513097A (sl)
AT (1) ATE386531T1 (sl)
AU (1) AU6823098A (sl)
CY (1) CY2607B2 (sl)
DE (1) DE59814173D1 (sl)
DK (1) DK0975347T3 (sl)
ES (1) ES2302350T3 (sl)
PT (1) PT975347E (sl)
SI (1) SI0975347T1 (sl)
WO (1) WO1998037894A1 (sl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
IL141335A0 (en) * 1998-08-26 2002-03-10 Smithkline Beecham Corp Therapies for treating pulmonary diseases
IL137429A0 (en) * 1999-07-28 2001-07-24 Pfizer Prod Inc Methods and compsitions for treating diseases and conditions of the eye
AU779991B2 (en) * 1999-08-10 2005-02-24 Board Of Regents, The University Of Texas System Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
HRP20020158B1 (en) * 1999-08-21 2007-08-31 Altana Pharma Ag Action of synergistic combination
TWI224966B (en) * 1999-11-02 2004-12-11 Pfizer Pharmaceutical composition (I) useful for treating or preventing pulmonary hypertension in a patient
HUP0301240A3 (en) 2000-06-05 2004-03-29 Altana Pharma B V Pyridazine compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors and pharmaceutical compositions containing them
AU2000270300A1 (en) * 2000-09-13 2002-03-26 Isis Innovation Limited Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
AU2002361417A1 (en) * 2001-12-17 2003-06-30 Altana Pharma Ag Use of selective PDE5 inhibitors for treating partial and global respiratory failure
US7276529B2 (en) * 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7208516B2 (en) * 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
NZ536050A (en) * 2002-04-12 2007-11-30 Celgene Corp Methods of identifying modulators of angiogenesis using stem cells with the proviso the stems cells are not totipotent
US20050118715A1 (en) * 2002-04-12 2005-06-02 Hariri Robert J. Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2003232148A1 (en) * 2002-05-16 2003-12-02 Pharmacia Corporation A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
MXPA04011404A (es) * 2002-05-16 2005-02-14 Pharmacia Corp Procedimientos para el tratamiento de enfermedades y afecciones respiratorias usando un inhibidor selectivo de inos.
CN1681510A (zh) * 2002-09-16 2005-10-12 爱尔康制造有限公司 Pde ⅳ抑制剂治疗血管生成的用途
EA009935B1 (ru) * 2002-11-27 2008-04-28 Никомед Гмбх Новая синергетическая комбинация, включающая рофлумиласт и формотерол
SI1567140T1 (sl) * 2002-11-27 2008-12-31 Nycomed Gmbh Sinergistična kombinacija, ki obsega roflumilastin (R;R)-formoterol
US20060083714A1 (en) * 2003-01-27 2006-04-20 Warner James M Combination of a pde iv inhibitor and a tnf-alpha antagonist
RU2543350C2 (ru) 2003-01-28 2015-02-27 Айронвуд Фармасьютикалз, Инк. Способы и композиции для лечения желудочно-кишечных расстройств
EP1620083A2 (en) * 2003-04-18 2006-02-01 Pharmacia & Upjohn Company LLC Combination therapies
ES2433661T3 (es) 2005-04-19 2013-12-12 Takeda Gmbh Roflumilast para el tratamiento de hipertensión pulmonar
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2382975A3 (en) 2006-05-09 2012-02-29 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2662491A1 (en) * 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2011515469A (ja) * 2008-03-24 2011-05-19 セルジーン コーポレイション シクロプロピル−ｎ−｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシフェニル）−２−（メチルスルホニル）エチル］−３−オキソイソインドリン−４−イル｝カルボキサミドを使用した乾癬又は乾癬性関節炎の治療
WO2010019450A2 (en) * 2008-08-09 2010-02-18 Nyles Bauer Synergizing active compounds for treating inflammation and other conditions
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2748607A1 (en) 2008-12-31 2010-07-08 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
WO2010098839A1 (en) * 2009-02-25 2010-09-02 Intra-Cellular Therapies, Inc. Pde 1 inhibitors for ophthalmic disorders
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
KR102138390B1 (ko) 2012-08-21 2020-07-27 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료에서 ｎｈｅ-매개된 역수송 저해를 위한 화합물 및 방법
EP3988120A1 (en) 2013-04-12 2022-04-27 Ardelyx, Inc. Nhe3-binding compounds and methods for inhibiting phosphate transport
WO2015200177A1 (en) 2014-06-23 2015-12-30 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
CN106333953A (zh) * 2015-07-08 2017-01-18 珠海津之敦医药科技有限公司 尤克那非新用途
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
MX2019008171A (es) 2017-01-09 2020-02-05 Ardelyx Inc Inhibidores del antiporte mediado por nhe.
CN110267944B (zh) 2017-01-09 2024-03-08 阿德利克斯股份有限公司 可用于治疗胃肠道病症的化合物
EP3937969A1 (en) 2019-03-14 2022-01-19 The Broad Institute, Inc. Compositions and methods for modulating cgrp signaling to regulate intestinal innate lymphoid cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3405181A1 (de) * 1984-02-10 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Neue carbacycline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPH01153634A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 吸入剤
IT1239281B (it) * 1989-10-27 1993-10-19 Indena Spa Composizioni per la riduzione dei depositi di grasso superfluo a base di principi attivi di origine vegetale ad attivita' agonista dell'adenilato ciclasi o/e ad attivita' antifosfodiesterasica
EP0504112A3 (en) * 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US5602110A (en) * 1994-08-31 1997-02-11 Case Western Reserve University Method and composition for treating cystic fibrosis

Also Published As

Publication number Publication date
ATE386531T1 (de) 2008-03-15
WO1998037894A1 (de) 1998-09-03
EP0975347B1 (de) 2008-02-20
DE59814173D1 (de) 2008-04-03
AU6823098A (en) 1998-09-18
JP2009073853A (ja) 2009-04-09
EP0975347A1 (de) 2000-02-02
PT975347E (pt) 2008-05-23
ES2302350T3 (es) 2008-07-01
JP2001513097A (ja) 2001-08-28
US6333354B1 (en) 2001-12-25
CY2607B2 (en) 2010-04-28
DK0975347T3 (da) 2008-06-16

Similar Documents

Publication Publication Date Title
SI0975347T1 (sl) Sinergistična kombinacija PDE inhibitorjev in agonistov adenilat ciklaze oziroma agonistov gvanil ciklize
UA41305C2 (uk) Cпосіб лікування незлоякісної гіперплазії простати та фармацевтична композиція для його здійснення
MY133569A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
ZA949539B (en) Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors.
AU2002302587A1 (en) Acne treatment with lipooxigenase inhibitors
RS65404A (en) N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substituent on the methyl useful as bradykinin antagonists
CA2260943A1 (en) Formulation of 5-ht agonists
EA199800626A1 (ru) Применение агониста ppar-гамма для лечения синдрома х
WO1999020260A3 (en) The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
DE60303441D1 (en) N-biphenylmethylaminocycloalkancarboxamid-derivative
BR0313470A (pt) Combinações terapêuticas de inibidores erbb quinase e terapias antineoplásicas
MY118301A (en) Local anesthetic for external use
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
ES2124765T3 (es) N-acil derivados de hidroxiaminas que tienen actividad eliminadora y que son utiles en patologias agudas y cronicas asociadas con los fenomenos de peroxidacion e inflamacion.
WO2000048583A3 (en) Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
FI962369A7 (fi) Farmaseuttinen formulointi myrkytyksen ehkäisemiseksi tai esihoidoksi organofosforisilla koliiniesteraasi-inhibiittoreilla
MX9707939A (es) Uso de antagonistas del factor inhibidor de la leucemia y la endotelina.
NZ331636A (en) AMPA receptor antagonist to treat dyskinesias associated with dopamine agonist therapy
WO1999045905A3 (en) Prophylaxis and treatment of migraine headaches with thromboxane synthetase inhibitors and/or receptor antagonists
JPS57128627A (en) Analgesic and antiphlogistic composition
CA2051520C (en) THERAPEUTIC METHOD
ES2115949T3 (es) Dihidrotestosterona para androgenoterapia.
NZ330616A (en) Potentiation of temozolomide toxicity in human cancer cells using inhibitors of ATase
Massingham The mechanism of action of theophylline in the frog heart
CA2177578A1 (en) Preventing and treating elevated intraocular pressure associated with administered or endogenous steroids using non-steroidal cyclooxygenase inhibitors